IPSS (Original) for Myelodysplastic Syndrome
Enter patient values below to estimate the original IPSS risk category for MDS.
What this IPSS MDS calculator does
This tool estimates risk using the original International Prognostic Scoring System (IPSS) for myelodysplastic syndromes (MDS). It combines three factors:
- Bone marrow blast percentage
- Cytogenetic risk group
- Number of peripheral blood cytopenias
The result is a risk group: Low, Intermediate-1, Intermediate-2, or High. Clinicians use this classification as one part of care planning, alongside age, comorbidities, symptoms, molecular data, and treatment goals.
How the IPSS score is calculated
1) Bone marrow blasts points
| Blast percentage | Points |
|---|---|
| < 5% | 0.0 |
| 5% to 10% | 0.5 |
| 11% to 20% | 1.5 |
| 21% to 30% | 2.0 |
2) Cytogenetics points
| Cytogenetic category | Points |
|---|---|
| Good | 0.0 |
| Intermediate | 0.5 |
| Poor | 1.0 |
3) Cytopenias points
Cytopenias are counted across three blood lines:
- Hemoglobin < 10 g/dL
- ANC < 1.8 x109/L
- Platelets < 100 x109/L
If 0 or 1 cytopenia is present, points = 0.0. If 2 or 3 cytopenias are present, points = 0.5.
Interpreting the total IPSS score
| Total score | Risk group | Typical prognostic trend (historical cohorts) |
|---|---|---|
| 0.0 | Low | Longest median survival in original data sets |
| 0.5 to 1.0 | Intermediate-1 | Intermediate prognosis; progression risk varies |
| 1.5 to 2.0 | Intermediate-2 | Higher risk of AML evolution and shorter survival |
| 2.5 or higher | High | Highest-risk group in original IPSS framework |
IPSS vs IPSS-R vs IPSS-M
If you are searching for an “IPSS MDS calculator,” you may actually need one of several models:
- IPSS (original): Classic 3-factor score used here.
- IPSS-R: Refined version with more cytogenetic granularity and deeper blood count cutoffs.
- IPSS-M: Adds molecular mutation data and generally improves risk discrimination.
In many modern hematology practices, IPSS-R or IPSS-M is preferred for current treatment decisions. Still, original IPSS remains useful for education, historical comparison, and quick baseline stratification.
Practical tips before using any MDS risk score
- Verify units (especially ANC and platelet units).
- Use high-quality marrow and cytogenetic data from the same clinical window.
- Interpret risk scores alongside symptoms, transfusion burden, frailty, and patient goals.
- Re-evaluate risk if disease biology changes or new test results emerge.
Frequently asked questions
Can I use this for all MDS patients?
Not always. The original IPSS was developed in specific patient cohorts and may not apply equally in every setting. For many patients today, clinicians prioritize IPSS-R or IPSS-M.
What if blasts are above 30%?
Blast percentages above 30% generally fall outside original IPSS use and may indicate AML-range disease biology. The calculator will flag this as out-of-range for classic IPSS interpretation.
Is this enough to choose treatment?
No. Treatment decisions in MDS require a full clinical assessment, including symptoms, performance status, molecular findings, comorbidities, and patient preferences.